Minigene‐based splicing analysis and ACMG/AMP‐based tentative classification of 56 ATM variants

The ataxia telangiectasia‐mutated (ATM) protein is a major coordinator of the DNA damage response pathway. ATM loss‐of‐function variants are associated with 2‐fold increased breast cancer risk. We aimed at identifying and classifying spliceogenic ATM variants detected in subjects of the large‐scale sequencing project BRIDGES. A total of 381 variants at the intron–exon boundaries were identified, 128 of which were predicted to be spliceogenic. After further filtering, we ended up selecting 56 variants for splicing analysis. Four functional minigenes (mgATM) spanning exons 4–9, 11–17, 25–29, and 49–52 were constructed in the splicing plasmid pSAD. Selected variants were genetically engineered into the four constructs and assayed in MCF‐7/HeLa cells. Forty‐eight variants (85.7%) impaired splicing, 32 of which did not show any trace of the full‐length (FL) transcript. A total of 43 transcripts were identified where the most prevalent event was exon/multi‐exon skipping. Twenty‐seven transcripts were predicted to truncate the ATM protein. A tentative ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology)‐based classification scheme that integrates mgATM data allowed us to classify 29 ATM variants as pathogenic/likely pathogenic and seven variants as likely benign. Interestingly, the likely pathogenic variant c.1898+2T>G generated 13% of the minigene FL‐transcript due to the use of a noncanonical GG‐5’‐splice‐site (0.014% of human donor sites). Circumstantial evidence in three ATM variants (leakiness uncovered by our mgATM analysis together with clinical data) provides some support for a dosage‐sensitive expression model in which variants producing ≥30% of FL‐transcripts would be predicted benign, while variants producing ≤13% of FL‐transcripts might be pathogenic. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

[1]  D. Easton,et al.  Splicing predictions, minigene analyses, and ACMG‐AMP clinical classification of 42 germline PALB2 splice‐site variants , 2021, The Journal of pathology.

[2]  A. Alt,et al.  Molecular basis of human ATM kinase inhibition , 2021, Nature Structural & Molecular Biology.

[3]  R. Hruban,et al.  Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. , 2021, JAMA oncology.

[4]  Jong-Won Kim,et al.  Performance Evaluation of SpliceAI for the Prediction of Splicing of NF1 Variants , 2021, Genes.

[5]  T. Paull,et al.  Cellular functions of the protein kinase ATM and their relevance to human disease , 2021, Nature Reviews Molecular Cell Biology.

[6]  O. Díez,et al.  Role of Splicing Regulatory Elements and In Silico Tools Usage in the Identification of Deep Intronic Splicing Variants in Hereditary Breast/Ovarian Cancer Genes , 2021, Cancers.

[7]  F. Couch,et al.  First international workshop of the ATM and cancer risk group (4-5 December 2019) , 2021, Familial Cancer.

[8]  D. Easton,et al.  RAD51D Aberrant Splicing in Breast Cancer: Identification of Splicing Regulatory Elements and Minigene-Based Evaluation of 53 DNA Variants , 2021, Cancers.

[9]  James M. Hodge,et al.  A Population-Based Study of Genes Previously Implicated in Breast Cancer. , 2021, The New England journal of medicine.

[10]  S. Narod.  Which Genes for Hereditary Breast Cancer? , 2021, The New England journal of medicine.

[11]  Jaana M. Hartikainen,et al.  Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. , 2021, The New England journal of medicine.

[12]  Tabea Riepe,et al.  Benchmarking deep learning splice prediction tools using functional splice assays , 2020, Human mutation.

[13]  Daniel Rueda,et al.  A Collaborative Effort to Define Classification Criteria for ATM Variants in Hereditary Cancer Patients. , 2020, Clinical chemistry.

[14]  D. Easton,et al.  Comprehensive Functional Characterization and Clinical Interpretation of 20 Splice-Site Variants of the RAD51C Gene , 2020, Cancers.

[15]  Leslie G. Biesecker,et al.  Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines , 2020, Human mutation.

[16]  D. Baralle,et al.  Blood RNA analysis can increase clinical diagnostic rate and resolve variants of uncertain significance , 2020, Genetics in Medicine.

[17]  Sitao Wu,et al.  Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes , 2020, npj Precision Oncology.

[18]  D. Kostrewa,et al.  Near-Complete Structure and Model of Tel1ATM from Chaetomium thermophilum Reveals a Robust Autoinhibited ATP State. , 2019, Structure.

[19]  P. Burgers,et al.  Cryo-EM Structure of Nucleotide-Bound Tel1ATM Unravels the Molecular Basis of Inhibition and Structural Rationale for Disease-Associated Mutations , 2019, Structure.

[20]  C. Gau,et al.  REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification , 2019, Scientific Reports.

[21]  Nephi A. Walton,et al.  Future directions for high‐throughput splicing assays in precision medicine , 2019, Human mutation.

[22]  E. Buratti,et al.  Mis‐splicing in breast cancer: identification of pathogenic BRCA2 variants by systematic minigene assays , 2019, The Journal of pathology.

[23]  Lea M. Starita,et al.  Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework , 2019, Genome Medicine.

[24]  Peijun Zhang,et al.  Structural insights into the activation of ATM kinase , 2019, Cell Research.

[25]  Yanhua Tian,et al.  Structural basis of allosteric regulation of Tel1/ATM kinase , 2019, Cell Research.

[26]  Sitao Wu,et al.  Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report , 2019, Journal of Medical Genetics.

[27]  David G. Knowles,et al.  Predicting Splicing from Primary Sequence with Deep Learning , 2019, Cell.

[28]  L. Biesecker,et al.  The ACMG/AMP reputable source criteria for the interpretation of sequence variants , 2018, Genetics in Medicine.

[29]  Heidi L Rehm,et al.  Updated recommendation for the benign stand‐alone ACMG/AMP criterion , 2018, Human mutation.

[30]  M. Vikkula,et al.  Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data. , 2018, Critical reviews in oncology/hematology.

[31]  Marina T. DiStefano,et al.  Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion , 2018, Human mutation.

[32]  Gabriel Capellá,et al.  Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations? , 2018, Front. Genet..

[33]  D. MacArthur,et al.  Response to Shah et al: Using high-resolution variant frequencies empowers clinical genome interpretation and enables investigation of genetic architecture , 2018, bioRxiv.

[34]  O. Díez,et al.  Characterization of spliceogenic variants located in regions linked to high levels of alternative splicing: BRCA2 c.7976+5G > T as a case study , 2018, Human mutation.

[35]  J. Coon,et al.  ATM directs DNA damage responses and proteostasis via genetically separable pathways , 2018, Science Signaling.

[36]  R. Nussbaum,et al.  Modeling the ACMG/AMP Variant Classification Guidelines as a Bayesian Classification Framework , 2018, Genetics in Medicine.

[37]  D. Watters,et al.  Neurodegeneration in ataxia‐telangiectasia: Multiple roles of ATM kinase in cellular homeostasis , 2018, Developmental dynamics : an official publication of the American Association of Anatomists.

[38]  A. Fersht,et al.  Structures of closed and open conformations of dimeric human ATM , 2017, Science Advances.

[39]  E. Velasco,et al.  Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18 , 2017, PLoS genetics.

[40]  Y. Camcıoğlu,et al.  Bladder Wall Telangiectasia in a Patient with Ataxia-Telangiectasia and How to Manage? , 2015, Case reports in pediatrics.

[41]  Matthias Heinig,et al.  Alternative Splicing Signatures in RNA‐seq Data: Percent Spliced in (PSI) , 2015, Current protocols in human genetics.

[42]  T. Paull.  Mechanisms of ATM Activation. , 2015, Annual review of biochemistry.

[43]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[44]  E. Velasco,et al.  Functional Classification of BRCA2 DNA Variants by Splicing Assays in a Large Minigene with 9 Exons , 2015, Human mutation.

[45]  A. Fischer,et al.  Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R. Munita,et al.  A comprehensive survey of non-canonical splice sites in the human transcriptome , 2014, Nucleic acids research.

[47]  Tina Pesaran,et al.  Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients , 2014, Genetics in Medicine.

[48]  O. Díez,et al.  Capillary Electrophoresis Analysis of Conventional Splicing Assays: IARC Analytical and Clinical Classification of 31 BRCA2 Genetic Variants , 2014, Human Mutation.

[49]  L. Nespoli,et al.  A Precocious Cerebellar Ataxia and Frequent Fever Episodes in a 16-Month-Old Infant Revealing Ataxia-Telangiectasia Syndrome , 2013, Case reports in immunology.

[50]  T. Bird,et al.  Novel mutations in ataxia telangiectasia and AOA2 associated with prolonged survival , 2012, Journal of the Neurological Sciences.

[51]  Jean-Philippe Vert,et al.  Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants , 2012, Human mutation.

[52]  A. Broeks,et al.  Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia‐telangiectasia: A genotype–phenotype study , 2012, Human mutation.

[53]  M. Stern,et al.  Underexpression and abnormal localization of ATM products in ataxia telangiectasia patients bearing ATM missense mutations , 2011, European Journal of Human Genetics.

[54]  T. Dörk,et al.  New mutations in the ATM gene and clinical data of 25 AT patients , 2011, neurogenetics.

[55]  E. Seemanová,et al.  Characterisation of ATM Mutations in Slavic Ataxia Telangiectasia Patients , 2011, NeuroMolecular Medicine.

[56]  D. Easton,et al.  Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours , 2011, British Journal of Cancer.

[57]  R. Gatti,et al.  Ataxia-Telangiectasia With Hyper-IgM and Wilms Tumor: Fatal Reaction to Irradiation , 2010, Journal of pediatric hematology/oncology.

[58]  Hong Ding,et al.  Lack of association between ATM C.1066-6T > G mutation and breast cancer risk: a meta-analysis of 8,831 cases and 4,957 controls , 2010, Breast Cancer Research and Treatment.

[59]  Alun Thomas,et al.  Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. , 2009, American journal of human genetics.

[60]  W. F. Abdo,et al.  Clinical spectrum of ataxia-telangiectasia in adulthood , 2009, Neurology.

[61]  E. Koonin,et al.  Accumulation of GC donor splice signals in mammals , 2008, Biology Direct.

[62]  P. Dundr,et al.  Contribution of mutations in ATM to breast cancer development in the Czech population. , 2008, Oncology reports.

[63]  R. Gatti,et al.  Large Genomic Mutations within the ATM Gene Detected by MLPA, Including a Duplication of 41 kb from Exon 4 to 20 , 2007, Annals of human genetics.

[64]  Guey-Shin Wang,et al.  Splicing in disease: disruption of the splicing code and the decoding machinery , 2007, Nature Reviews Genetics.

[65]  J. Kere,et al.  Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. , 2006, Carcinogenesis.

[66]  R. Gatti,et al.  ATM mutations in Italian families with ataxia telangiectasia include two distinct large genomic deletions , 2006, Human mutation.

[67]  M. Lavin,et al.  Involvement of novel autophosphorylation sites in ATM activation , 2006, The EMBO journal.

[68]  T. Cooper.  Use of minigene systems to dissect alternative splicing elements. , 2005, Methods.

[69]  R. Gatti,et al.  ATM Gene Founder Haplotypes and Associated Mutations in Polish Families with Ataxia‐Telangiectasia , 2005, Annals of human genetics.

[70]  M. Lavin,et al.  ATM mutations, haplotype analysis, and immunological status of Russian patients with ataxia telangiectasia , 2005, Human mutation.

[71]  D. Stoppa-Lyonnet,et al.  Cancer risk according to type and location of ATM mutation in ataxia‐telangiectasia families , 2005, Genes, chromosomes & cancer.

[72]  T. Dörk,et al.  Slow progression of ataxia‐telangiectasia with double missense and in frame splice mutations , 2004, American journal of medical genetics. Part A.

[73]  Catarina D. Campbell,et al.  Independent mutational events are rare in the ATM gene: Haplotype prescreening enhances mutation detection rate , 2003, Human mutation.

[74]  Christopher B. Burge,et al.  Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals , 2003, RECOMB '03.

[75]  O. Sanal,et al.  Comprehensive scanning of the ATM gene with DOVAM‐S , 2003, Human mutation.

[76]  Sara G. Becker-Catania,et al.  Early diagnosis of ataxia-telangiectasia using radiosensitivity testing. , 2002, The Journal of pediatrics.

[77]  A. Børresen-Dale,et al.  ATM mutations in Finnish breast cancer patients , 2002, Journal of medical genetics.

[78]  T A Thanaraj,et al.  Human GC-AG alternative intron isoforms with weak donor sites show enhanced consensus at acceptor exon positions. , 2001, Nucleic acids research.

[79]  A. Børresen-Dale,et al.  Characterization of ATM mutations in 41 Nordic families with Ataxia Telangiectasia , 2000, Human mutation.

[80]  Sara G. Becker-Catania,et al.  Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. , 1999, American journal of human genetics.

[81]  T. Dörk,et al.  Characterization of ATM gene mutations in 66 ataxia telangiectasia families. , 1999, Human molecular genetics.

[82]  A. Børresen-Dale,et al.  Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations. , 1998, American journal of human genetics.

[83]  A. Broeks,et al.  ATM germline mutations in classical ataxia‐telangiectasia patients in the Dutch population , 1998, Human mutation.

[84]  M. Lovett,et al.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.